Welcoming New European Supporter, Patient Conversations & New MBI Study
New European Education Supporter
Join us in welcoming Dr. Thiemo van Nijnatten as DBI’s European Education Supporter from The Netherlands! T. van Nijnatten is a Breast and Nuclear Radiologist at Maastricht UMC+ and Dutch Expert Center for Screening (LRCB). He is also executive board member of the European Society of Breast Imaging (EUSOBI) and the current chair of the EUSOBI Young Club Committee.
Ready for Patient Conversations?
DBI’s Breast Cancer Awareness Month education outreach include this article in Applied Radiology, FDA Breast Density Reporting is in Effect. Ready for Patient Conversations? by executive director JoAnn Pushkin.
New MBI Study
Annual Molecular Breast Imaging Improves Cancer Detection in Dense Breasts: Hruska et al reported results from the prospective multicenter Density MATTERS (Molecular Breast Imaging and Tomosynthesis to Eliminate the Reservoir) trial in Radiology. Among nearly 3000 women with dense breasts, 87% of whom were not at high risk, adding 99mTc-sestamibi molecular breast imaging (MBI) to tomosynthesis (DBT) each year for two years, with one additional year of follow-up showed:
- Improved detection of early breast cancer each year.1,2
- Reduced false positive recalls with the second round of screening.3
- Interval cancer rates were very low with combined screening DBT+MBI.4
Specifically:
1 In year 1, the incremental cancer detection rate from adding MBI to tomosynthesis was 6.7/1000 (95%CI 4.2, 10.6), with tomosynthesis alone depicting 5.0/1000. In year 2, the incremental cancer detection rate from adding MBI to tomosynthesis was 3.5/1000 (95%CI 1.7, 6.8), with tomosynthesis alone depicting 5.8/1000.
2 Of 29 women with cancer seen only on MBI, 21 (72%) were invasive (median size 0.9 cm, range 0.4 to 2.6) and 18/21 (86%) were node negative. Six women (20%) had locally advanced breast cancers.
3 False positive recall rate in year 1 was 16.9% after combined DBT+MBI screening, compared to 8.1% for DBT alone (added false positive recall rate due to MBI of 8.8% in year 1), and 12.9% after combined DBT+MBI screening in year 2, compared to 8.4% for DBT alone (added recall rate due to MBI of 4.5% in year 2).
4 Symptomatic interval cancer rate was 2/2978 (0.7%) in year 1 and 2/2590 (0.8%) in year 2.